アルツハイマー病診断薬・治療薬市場：製品、病期、エンドユーザー別-2025-2030年世界予測

アルツハイマー病診断薬・治療薬市場は、2023年に67億5,000万米ドルと評価され、2024年には72億6,000万米ドルに達すると予測され、CAGR 8.00%で成長し、2030年には115億7,000万米ドルに達すると予測されています。

アルツハイマー病診断薬・治療薬市場は、世界中で数百万人が罹患している進行性の神経変性疾患であるアルツハイマー病の特定と治療に焦点を当てています。対象範囲には、MRIやPETスキャンなどの画像技術からバイオマーカーや遺伝子検査まで、幅広い診断ソリューションが含まれます。治療的介入には、症状管理や疾患修飾療法を対象とした医薬品が含まれます。市場の必要性は、世界の高齢化に伴うアルツハイマー病の有病率の増加により、早期診断と効果的な治療の必要性が強調されていることが背景にあります。診断薬は臨床現場でアルツハイマーの存在を確認するために適用され、治療薬は病気の進行を管理し、遅らせるために使用されます。エンドユーザーは主に病院、診断研究所、研究機関、長期介護施設などです。主な成長要因としては、診断技術の進歩、研究開発投資の増加、早期介入への注目の高まりなどが挙げられます。個別化医療アプローチの開発や疾患修飾治療における画期的な進歩にビジネスチャンスがあります。企業は、AI主導の診断ツールに投資し、医薬品開発のためのパートナーシップを追求することで、これらを活用することができます。しかし、高い開発コスト、厳しい規制環境、効果的な疾患修飾治療の実現に向けた課題などの制約があります。また、新興国市場における認知度の低さや、医療へのアクセスに影響を及ぼす社会経済的格差も市場開拓の妨げとなっています。イノベーションは、治療効果を向上させるためのニューロイメージングの進歩、バイオマーカーの発見、新規ドラッグデリバリーシステムにおいて盛んになる可能性があります。デジタルヘルスツールや遠隔診断プラットフォームの利用へと大きくシフトしており、さらなる拡大の機会を提供しています。市場は依然としてダイナミックであり、進化する技術、学界と産業界の協力関係の強化、効果的なアルツハイマー病治療に対するアンメットニーズの高まりがその原動力となっています。企業がこのような複雑な状況を乗り切るには、共同研究を重視し、新たな技術を取り入れることが、市場での存在感と成長を持続させるために不可欠です。

市場力学：急速に進化するアルツハイマー病診断薬・治療薬市場の主要市場インサイトを公開

アルツハイマー病診断薬・治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界の老年人口の増加とアルツハイマー病の罹患率の上昇
  • アルツハイマー病の診断および医薬品開発におけるバイオマーカーの利用の増加
  • パイプラインにある多数のアルツハイマー病治療薬の利用可能性
• 市場抑制要因
  • アルツハイマー病の早期発見が困難であるという懸念
• 市場機会
  • 新規アルツハイマー病診断薬および治療薬の開発への注目の高まり
  • アルツハイマー病の診断および医薬品開発に対する政府支援の増加
• 市場の課題
  • アルツハイマー病の診断と治療に関する臨床研究の高い失敗率

ポーターの5つの力：アルツハイマー病診断薬・治療薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：アルツハイマー病診断薬・治療薬市場における外部からの影響の把握

外部マクロ環境要因は、アルツハイマー病診断薬・治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析アルツハイマー病診断薬・治療薬市場における競合情勢の把握

アルツハイマー病診断薬・治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的な意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスアルツハイマー病診断薬・治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、アルツハイマー病診断薬・治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨アルツハイマー病診断薬・治療薬市場における成功への道筋を描く

アルツハイマー病診断薬・治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で高齢者人口が増加し、アルツハイマー病の発症率が上昇
    • アルツハイマー病の診断と医薬品開発におけるバイオマーカーの利用増加
    • パイプラインに多数のアルツハイマー病治療薬が存在
  • 抑制要因
    • アルツハイマー病の早期発見の難しさに関する懸念
  • 機会
    • アルツハイマー病の新しい診断法と治療法の開発への注目が高まる
    • アルツハイマー病の診断と治療薬開発に対する政府の支援が増加
  • 課題
    • アルツハイマー病の診断と治療に関する臨床研究の失敗率が高い
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 アルツハイマー病診断薬・治療薬市場：製品別

• 診断
  • バイオマーカー
  • 認知評価
  • イメージング技術
• 治療薬
  • コリンエステラーゼ阻害剤
  • N-メチル-D-アスパラギン酸受容体拮抗薬

第7章 アルツハイマー病診断薬・治療薬市場病気のステージ別

• 早い
• 適度
• 重度

第8章 アルツハイマー病診断薬・治療薬市場：エンドユーザー別

• 学術調査機関
• 診断研究所
• 病院・クリニック

第9章 南北アメリカのアルツハイマー病診断薬・治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のアルツハイマー病診断薬・治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのアルツハイマー病診断薬・治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbvie Inc.
• AC Immune SA
• Alector, Inc.
• Alzheon, Inc.
• Amylyx Pharmaceuticals, Inc.
• AstraZeneca PLC
• Biogen Inc.
• BioXcel Therapeutics Inc.
• Bristol-Myers Squibb Company
• Codiak BioSciences
• Cognoptix Inc.
• Corium Inc.
• Denali Therapeutics Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• F. Hoffmann-La Roche AG
• Grifols, S.A.
• H. Lundbeck A/S
• Lexeo Therapeutics, Inc.
• Luye Pharma Group
• Merz Pharma GmbH & Co. KGaA
• MODAG GmbH
• Muna Therapeutics
• Novartis AG
• Pfizer, Inc.
• Siemens Healthineers AG
• Supernus Pharmaceuticals, Inc.
• TauRx Therapeutics Ltd.
• VectorY Therapeutics
• Vigil Neuroscience, Inc.
• Voyager Therapeutics, Inc.
• Zydus Lifesciences Limited

LIST OF FIGURES

• FIGURE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET RESEARCH PROCESS
• FIGURE 2. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET DYNAMICS
• TABLE 7. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY BIOMARKER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COGNITIVE ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY IMAGING TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY CHOLINESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY N-METHYL-D-ASPARTATE RECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY EARLY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY MODERATE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY SEVERE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 31. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 35. ARGENTINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 38. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 39. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 40. BRAZIL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 41. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 42. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 43. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 44. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 45. CANADA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 46. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 47. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 48. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 49. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 50. MEXICO ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 52. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 53. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 54. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 55. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 56. UNITED STATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 57. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 58. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 59. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 60. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 61. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 62. ASIA-PACIFIC ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 63. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 64. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 65. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 66. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 67. AUSTRALIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 68. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 69. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 70. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 71. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 72. CHINA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 75. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 76. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 77. INDIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 79. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 80. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 81. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 82. INDONESIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 83. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 84. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 85. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 86. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 87. JAPAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 89. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 90. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 91. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 92. MALAYSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 93. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 94. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 95. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 96. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 97. PHILIPPINES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 99. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 100. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 101. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 102. SINGAPORE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 105. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 106. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 107. SOUTH KOREA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 108. TAIWAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 109. TAIWAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 110. TAIWAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 111. TAIWAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 112. TAIWAN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 113. THAILAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 114. THAILAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 115. THAILAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 116. THAILAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 117. THAILAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. VIETNAM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 119. VIETNAM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 120. VIETNAM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 121. VIETNAM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 122. VIETNAM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 124. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 125. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 126. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 127. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 128. EUROPE, MIDDLE EAST & AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 129. DENMARK ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 130. DENMARK ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 131. DENMARK ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 132. DENMARK ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 133. DENMARK ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 134. EGYPT ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 135. EGYPT ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 136. EGYPT ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 137. EGYPT ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 138. EGYPT ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. FINLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 140. FINLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 141. FINLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 142. FINLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 143. FINLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 144. FRANCE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 145. FRANCE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 146. FRANCE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 147. FRANCE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 148. FRANCE ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 149. GERMANY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 150. GERMANY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 151. GERMANY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 152. GERMANY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 153. GERMANY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 154. ISRAEL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 155. ISRAEL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 156. ISRAEL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 157. ISRAEL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 158. ISRAEL ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. ITALY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. ITALY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 161. ITALY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 162. ITALY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 163. ITALY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 164. NETHERLANDS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 165. NETHERLANDS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 166. NETHERLANDS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 167. NETHERLANDS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 168. NETHERLANDS ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 169. NIGERIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 170. NIGERIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 171. NIGERIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 172. NIGERIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 173. NIGERIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 174. NORWAY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 175. NORWAY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 176. NORWAY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 177. NORWAY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 178. NORWAY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. POLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 180. POLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 181. POLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 182. POLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 183. POLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 184. QATAR ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 185. QATAR ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 186. QATAR ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 187. QATAR ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 188. QATAR ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 189. RUSSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 190. RUSSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 191. RUSSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 192. RUSSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 193. RUSSIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 194. SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 195. SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 196. SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 197. SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 198. SAUDI ARABIA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 199. SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 200. SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 201. SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 202. SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 203. SOUTH AFRICA ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 204. SPAIN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 205. SPAIN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 206. SPAIN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 207. SPAIN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 208. SPAIN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. SWEDEN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. SWEDEN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 211. SWEDEN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 212. SWEDEN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 213. SWEDEN ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 214. SWITZERLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 215. SWITZERLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 216. SWITZERLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 217. SWITZERLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 218. SWITZERLAND ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 219. TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 220. TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 221. TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 222. TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 223. TURKEY ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 224. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 225. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 226. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 227. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 228. UNITED ARAB EMIRATES ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 229. UNITED KINGDOM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 230. UNITED KINGDOM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DIAGNOSTICS, 2018-2030 (USD MILLION)
• TABLE 231. UNITED KINGDOM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY THERAPEUTICS, 2018-2030 (USD MILLION)
• TABLE 232. UNITED KINGDOM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY DISEASE STAGE, 2018-2030 (USD MILLION)
• TABLE 233. UNITED KINGDOM ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 234. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 235. ALZHEIMER'S DISEASE DIAGNOSTICS & THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Alzheimer's Disease Diagnostics & Therapeutics Market was valued at USD 6.75 billion in 2023, expected to reach USD 7.26 billion in 2024, and is projected to grow at a CAGR of 8.00%, to USD 11.57 billion by 2030.

The Alzheimer's Disease Diagnostics & Therapeutics market focuses on identifying and treating Alzheimer's disease, a progressive neurodegenerative disorder affecting millions globally. The scope covers diagnostic solutions that range from imaging technologies like MRI and PET scans to biomarkers and genetic testing. Therapeutic interventions include pharmaceuticals targeting symptom management and disease-modifying therapies. The market's necessity is driven by the increasing prevalence of Alzheimer's due to aging populations worldwide, emphasizing early diagnosis and the need for effective treatments. Diagnostics are applied in clinical settings to confirm Alzheimer's presence, while therapies are used to manage and potentially slow disease progression. End-users primarily include hospitals, diagnostic laboratories, research institutes, and long-term care facilities. Key growth factors include technological advancements in diagnostics, increased R&D investment, and a heightened focus on early intervention. Opportunities lie in the development of personalized medicine approaches and breakthroughs in disease-modifying treatments. Companies can capitalize on these by investing in AI-driven diagnostic tools and pursuing partnerships for drug development. However, limitations include high development costs, strict regulatory environments, and challenges in achieving effective disease-modifying treatments. Market growth is also hindered by limited awareness in developing regions and socio-economic disparities affecting access to care. Innovation can thrive in neuroimaging advancements, biomarker discovery, and novel drug delivery systems to improve therapeutic efficacy. There's a significant shift towards using digital health tools and remote diagnostic platforms, offering further opportunities for expansion. The market remains dynamic, driven by evolving technologies, increasing collaboration between academia and industry, and an urgent unmet need for effective Alzheimer's interventions. As companies navigate these complexities, focusing on collaborations and embracing emerging technologies will be vital for sustained market presence and growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Alzheimer's Disease Diagnostics & Therapeutics Market

The Alzheimer's Disease Diagnostics & Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Growing geriatric population and rising incidence of Alzheimer's disease globally
  • Increasing use of biomarkers in Alzheimer's disease diagnosis and drug development
  • Availability of large number of Alzheimer's disease drugs in pipeline
• Market Restraints
  • Concerns associated with difficulties with early detection of Alzheimer's disease
• Market Opportunities
  • Increasing focus on development of novel Alzheimer's disease diagnostics and therapeutics
  • Rising government support for Alzheimer's diagnosis and drug development
• Market Challenges
  • High failure rates of clinical studies related to Alzheimer's disease diagnosis and treatment

Porter's Five Forces: A Strategic Tool for Navigating the Alzheimer's Disease Diagnostics & Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Alzheimer's Disease Diagnostics & Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Alzheimer's Disease Diagnostics & Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Alzheimer's Disease Diagnostics & Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Alzheimer's Disease Diagnostics & Therapeutics Market

A detailed market share analysis in the Alzheimer's Disease Diagnostics & Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Alzheimer's Disease Diagnostics & Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Alzheimer's Disease Diagnostics & Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Alzheimer's Disease Diagnostics & Therapeutics Market

A strategic analysis of the Alzheimer's Disease Diagnostics & Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Alzheimer's Disease Diagnostics & Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., AC Immune SA, Alector, Inc., Alzheon, Inc., Amylyx Pharmaceuticals, Inc., AstraZeneca PLC, Biogen Inc., BioXcel Therapeutics Inc., Bristol-Myers Squibb Company, Codiak BioSciences, Cognoptix Inc., Corium Inc., Denali Therapeutics Inc., Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, Grifols, S.A., H. Lundbeck A/S, Lexeo Therapeutics, Inc., Luye Pharma Group, Merz Pharma GmbH & Co. KGaA, MODAG GmbH, Muna Therapeutics, Novartis AG, Pfizer, Inc., Siemens Healthineers AG, Supernus Pharmaceuticals, Inc., TauRx Therapeutics Ltd., VectorY Therapeutics, Vigil Neuroscience, Inc., Voyager Therapeutics, Inc., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Alzheimer's Disease Diagnostics & Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Diagnostics and Therapeutics. The Diagnostics is further studied across Biomarker, Cognitive Assessment, and Imaging Technologies. The Therapeutics is further studied across Cholinesterase Inhibitors and N-Methyl-D-Aspartate Receptor Antagonists.
• Based on Disease Stage, market is studied across Early, Moderate, and Severe.
• Based on End-User, market is studied across Academic Research Institutes, Diagnostics Laboratories, and Hospitals & Clinics.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing geriatric population and rising incidence of Alzheimer's disease globally
    • 5.1.1.2. Increasing use of biomarkers in Alzheimer's disease diagnosis and drug development
    • 5.1.1.3. Availability of large number of Alzheimer's disease drugs in pipeline
  • 5.1.2. Restraints
    • 5.1.2.1. Concerns associated with difficulties with early detection of Alzheimer's disease
  • 5.1.3. Opportunities
    • 5.1.3.1. Increasing focus on development of novel Alzheimer's disease diagnostics and therapeutics
    • 5.1.3.2. Rising government support for Alzheimer's diagnosis and drug development
  • 5.1.4. Challenges
    • 5.1.4.1. High failure rates of clinical studies related to Alzheimer's disease diagnosis and treatment
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Alzheimer's Disease Diagnostics & Therapeutics Market, by Product

• 6.1. Introduction
• 6.2. Diagnostics
  • 6.2.1. Biomarker
  • 6.2.2. Cognitive Assessment
  • 6.2.3. Imaging Technologies
• 6.3. Therapeutics
  • 6.3.1. Cholinesterase Inhibitors
  • 6.3.2. N-Methyl-D-Aspartate Receptor Antagonists

7. Alzheimer's Disease Diagnostics & Therapeutics Market, by Disease Stage

• 7.1. Introduction
• 7.2. Early
• 7.3. Moderate
• 7.4. Severe

8. Alzheimer's Disease Diagnostics & Therapeutics Market, by End-User

• 8.1. Introduction
• 8.2. Academic Research Institutes
• 8.3. Diagnostics Laboratories
• 8.4. Hospitals & Clinics

9. Americas Alzheimer's Disease Diagnostics & Therapeutics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Alzheimer's Disease Diagnostics & Therapeutics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Alzheimer's Disease Diagnostics & Therapeutics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbvie Inc.
• 2. AC Immune SA
• 3. Alector, Inc.
• 4. Alzheon, Inc.
• 5. Amylyx Pharmaceuticals, Inc.
• 6. AstraZeneca PLC
• 7. Biogen Inc.
• 8. BioXcel Therapeutics Inc.
• 9. Bristol-Myers Squibb Company
• 10. Codiak BioSciences
• 11. Cognoptix Inc.
• 12. Corium Inc.
• 13. Denali Therapeutics Inc.
• 14. Eisai Co., Ltd.
• 15. Eli Lilly and Company
• 16. F. Hoffmann-La Roche AG
• 17. Grifols, S.A.
• 18. H. Lundbeck A/S
• 19. Lexeo Therapeutics, Inc.
• 20. Luye Pharma Group
• 21. Merz Pharma GmbH & Co. KGaA
• 22. MODAG GmbH
• 23. Muna Therapeutics
• 24. Novartis AG
• 25. Pfizer, Inc.
• 26. Siemens Healthineers AG
• 27. Supernus Pharmaceuticals, Inc.
• 28. TauRx Therapeutics Ltd.
• 29. VectorY Therapeutics
• 30. Vigil Neuroscience, Inc.
• 31. Voyager Therapeutics, Inc.
• 32. Zydus Lifesciences Limited